Dr Hilary Cass, who authored the independent review known as the Cass report, says a proposed clinical trial of puberty blockers could reduce harm to children. Speaking about the trial, Cass argues that more children will be harmed if the study does not proceed than if it does. The trial is presented as a way to gather stronger evidence on the effects and risks of puberty blockers for young people who experience gender dysphoria.
The BBC coverage focuses on Cass’s assessment that delaying or avoiding research would carry real consequences for patients, while conducting a structured study would help clinicians and policymakers make better-informed decisions. The reporting reflects the broader debate around puberty blockers by emphasizing the need for evidence rather than taking a position based solely on existing data.
Cass’s comments frame the trial as a harm-reduction step through improved understanding of outcomes, rather than as a statement about individual cases. The article does not provide new trial results, but highlights the rationale for running the study.
